(Q30422919)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Cynthia X Ma

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Matthew J C Ellis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gina R Petroni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Zhanfang Guo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Shi-Rong Cai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Christine E Ryan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Craig Lockhart

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Michael J Naughton

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Timothy J Pluard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Christiana M Brenin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Joel Picus

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Allison N Creekmore

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Tibu Mwandoro

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Erin R Yarde

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Jerry Reed

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Philip S Bernard

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mark Watson

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Laurence A Doyle

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Janet Dancey

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Helen Piwnica-Worms

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Paula M Fracasso

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

15 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

483-492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 2.5 Generic

20 February 2020

copyright license

start time

15 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10549-012-2378-9

0 references

cites work

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Targeting triple-negative breast cancer: optimising therapeutic outcomes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Dissecting the heterogeneity of triple-negative breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Targeting the S and G2 checkpoint to treat cancer.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Triple-Negative Breast Cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

New insights into checkpoint kinase 1 in the DNA damage response signaling network

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Supervised risk predictor of breast cancer based on intrinsic subtypes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Triple-negative breast cancer: clinical features and patterns of recurrence

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Targeting checkpoint kinase 1 in cancer therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

PDK1, the master regulator of AGC kinase signal transduction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Cell cycle checkpoints and their impact on anticancer therapeutic strategies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Protein kinases: getting NEKed for S6K activation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Participation of p53 protein in the cellular response to DNA damage

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3539064

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

20 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10549-012-2378-9

Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10549-012-2378-9

p53 as a specific prognostic factor in triple-negative breast cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10549-012-2378-9

Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)

21 January 2018

1 reference

12 December 2020

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

12 December 2020

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

1 reference

12 December 2020

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

12 December 2020

UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function

1 reference

12 December 2020

10.1007/S10549-012-2378-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 February 2020

1029818814

0 references

Fatcat ID

release_ptw75o43ondmjlwhbuuwg6f4fe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ptw75o43ondmjlwhbuuwg6f4fe

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

23242585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242585%20AND%20SRC:MED&resulttype=core&format=json